Extended indication Extension of indication to include the treatment of diabetes mellitus in adolescents and children ag
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Insulin lispro
Domain Metabolism and Endocrinology
Reason of inclusion Generic
Main indication Diabetes
Extended indication Extension of indication to include the treatment of diabetes mellitus in adolescents and children aged 1 year and above.
Proprietary name Lyumjev
Manufacturer Eli Lilly
Mechanism of action Insulin preparation
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Submission date January 2022
Expected Registration November 2022
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.